Advances in the Management of Early-Stage Triple-Negative Breast Cancer.

Bhardwaj, Prarthna V; Wang, Yue; Brunk, Elizabeth; Spanheimer, Philip M; Abdou, Yara G

Bhardwaj, Prarthna V; Wang, Yue; Brunk, Elizabeth; Spanheimer, Philip M; Abdou, Yara G.

Afiliación

Bhardwaj PV; Division of Hematology-Oncology, University of Massachusetts Chan Medical School-Baystate, Springfield, MA 01199, USA.
Wang Y; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Brunk E; Curriculum in Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Spanheimer PM; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Abdou YG; Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Int J Mol Sci ; 24(15)2023 Aug 05.

Article en En | MEDLINE | ID: mdl-37569851

Palabras clave

PARP inhibitors; breast cancer; breast surgery; early-stage TNBC; immunotherapy; neoadjuvant chemotherapy; targeted therapy; triple-negative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Int J Mol Sci Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google